View Past PerformanceEpigenomics バランスシートの健全性財務の健全性 基準チェック /06Epigenomicsの健全性を判断するにはデータが不十分です主要情報n/a負債資本比率€11.38m負債インタレスト・カバレッジ・レシオn/a現金€764.00kエクイティ€0負債合計€11.86m総資産€11.86m財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 21Epigenomics AG, Annual General Meeting, May 27, 2026Epigenomics AG, Annual General Meeting, May 27, 2026, at 09:00 W. Europe Standard Time.お知らせ • Apr 03Epigenomics AG to Report Fiscal Year 2025 Results on Apr 02, 2026Epigenomics AG announced that they will report fiscal year 2025 results on Apr 02, 2026お知らせ • Jul 17Epigenomics AG, Annual General Meeting, Aug 27, 2025Epigenomics AG, Annual General Meeting, Aug 27, 2025, at 10:30 W. Europe Standard Time.お知らせ • Nov 29+ 2 more updatesEpigenomics AG, Annual General Meeting, May 29, 2024Epigenomics AG, Annual General Meeting, May 29, 2024.お知らせ • Oct 12New Day Diagnostics, LLC acquired Substantially all of Assets of Epigenomics AG for $9.8 million.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG for $9.8 million on July 24, 2023. Under the terms of consideration, As consideration for the sale, Epigenomics AG will receive a purchase price of up to USD 12.05 million, which can be broken down as follows: Cash payments of USD 1.8 million: USD 0.5 million on the closing date, USD 1.0 million on December 1, 2023 and USD 0.3 million on June 30, 2024. Further cash payments of up to USD 8.0 million contingent on the achievement of certain milestones related to Epi proColon and foremost Epi proColon “Next-Gen”. An interest in the acquirer of 3.0%, valued at least at USD 2.25 million. In addition, the Company will receive royalty or earn-out payments, in the form of royalties linked to the commercialization of the “Next-Gen”-Test. These payments extend probably until October 2043, the year in which patent protection for the product is expected to expire. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property along with all patents as well as the entire biobank, and thus all of its assets within the meaning of Section 179a of the German Stock Corporation Act (AktG), to the acquirer. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer. The agreement is subject to certain closing conditions, including the approval at the Company’s Extraordinary General Meeting. The sale of the assets to New Day Diagnostics is expected to enable the commercialization of Epi proColon “Next-Gen” and secure future cash flows for Epigenomics AG. As of September 14, 2023, Extraordinary General Meeting of Epigenomics approved the transaction. The closing of the agreement remains subject to customary closing conditions, and both parties are diligently working towards its completion. TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors. New Day Diagnostics, LLC completed the acquisition of Substantially all of Assets of Epigenomics AG on October 10, 2023.お知らせ • Jul 26New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG on July 24, 2023. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer.TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors.お知らせ • Jun 13Epigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5mEpigenomics AG (XTRA:ECX1) shares more than doubled in value on June 12, 2023 after it said it is holding talks with an unidentified U.S. company to sell nearly all of its assets for around $11.5 million. The German medical diagnostic company said the potential deal, which is unbinding and therefore could still fail, relates to the patents and other rights of its blood tests to screen for colon cancer and all blood samples owned by Epigenomics. Current negotiations place the deal closing in December, Epigenomics said. The unidentified acquirer would also have to pay royalties and other costs associated with the potential commercialization of a diagnostic test in development.お知らせ • May 20Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023Epigenomics AG announced that Member of the Executive Board, President, and Chief Scientific Officer Dr. Andrew Lukowiak, and the Company's Supervisory Board agreed on his resignation from the Company and the Executive Board effective May 31, 2023. Between now and the resignation date Dr. Lukowiak will continue to support the Company’s restructuring efforts in coordination with the Supervisory Board. The Company continues to be committed to maximizing the value of its technology through corporate partnering, licensing and/or asset sales. Dr. Lukowiak has been a Member of the Executive Board, President, and CSO of Epigenomics AG since December 2021. His broad contributions across the organization have been instrumental in furthering the Company’s colorectal cancer diagnostics’ program, including his systematic optimization of R&D structure and processes, as well as his execution of complementary partnerships. However, in recent months, in the current capital market environment, the Company has been unable to raise additional capital to secure funding for the FDA pivotal study of the "Next-Gen" test. In response, the restructuring of the Company was initiated on February 15, 2023 to minimize costs. Against this backdrop, the resignation of Dr. Andrew Lukowiak now also takes place.お知らせ • Nov 09+ 2 more updatesEpigenomics AG to Report Q3, 2023 Results on Nov 09, 2023Epigenomics AG announced that they will report Q3, 2023 results on Nov 09, 2023財務状況分析短期負債: EPGN.Fは マイナスの株主資本 を有しており、これは 短期資産 が 短期負債 をカバーしていないことよりも深刻な状況です。長期負債: EPGN.Fは株主資本がマイナスであり、これは短期資産が 長期負債 をカバーしていないことよりも深刻な状況です。デット・ツー・エクイティの歴史と分析負債レベル: EPGN.Fの 純負債対資本比率 を計算して 満足できる ものであるかどうかを判断するにはデータが不十分です。負債の削減: EPGN.Fの株主資本はマイナスなので、時間の経過とともに負債が減少したかどうかを確認する必要はありません。貸借対照表キャッシュ・ランウェイ分析過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。安定したキャッシュランウェイ: 現在のフリーキャッシュフローに基づいて、 EPGN.Fに十分なキャッシュランウェイがあるかどうかを判断するにはデータが不十分です。キャッシュランウェイの予測: EPGN.Fの フリー キャッシュ フロー が過去のレートに基づいて増加または減少し続ける場合、十分な キャッシュ ランウェイ があるかどうかを判断するためのデータが不十分です。健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2025/10/15 18:44終値2025/07/18 00:00収益2025/06/30年間収益2024/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Epigenomics AG 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Hans Bjorn BostromEdison Investment ResearchSimon ScholesFirst Berlin Equity Research GmbHBryan BrokmeierMaxim Group2 その他のアナリストを表示
お知らせ • Apr 21Epigenomics AG, Annual General Meeting, May 27, 2026Epigenomics AG, Annual General Meeting, May 27, 2026, at 09:00 W. Europe Standard Time.
お知らせ • Apr 03Epigenomics AG to Report Fiscal Year 2025 Results on Apr 02, 2026Epigenomics AG announced that they will report fiscal year 2025 results on Apr 02, 2026
お知らせ • Jul 17Epigenomics AG, Annual General Meeting, Aug 27, 2025Epigenomics AG, Annual General Meeting, Aug 27, 2025, at 10:30 W. Europe Standard Time.
お知らせ • Nov 29+ 2 more updatesEpigenomics AG, Annual General Meeting, May 29, 2024Epigenomics AG, Annual General Meeting, May 29, 2024.
お知らせ • Oct 12New Day Diagnostics, LLC acquired Substantially all of Assets of Epigenomics AG for $9.8 million.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG for $9.8 million on July 24, 2023. Under the terms of consideration, As consideration for the sale, Epigenomics AG will receive a purchase price of up to USD 12.05 million, which can be broken down as follows: Cash payments of USD 1.8 million: USD 0.5 million on the closing date, USD 1.0 million on December 1, 2023 and USD 0.3 million on June 30, 2024. Further cash payments of up to USD 8.0 million contingent on the achievement of certain milestones related to Epi proColon and foremost Epi proColon “Next-Gen”. An interest in the acquirer of 3.0%, valued at least at USD 2.25 million. In addition, the Company will receive royalty or earn-out payments, in the form of royalties linked to the commercialization of the “Next-Gen”-Test. These payments extend probably until October 2043, the year in which patent protection for the product is expected to expire. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property along with all patents as well as the entire biobank, and thus all of its assets within the meaning of Section 179a of the German Stock Corporation Act (AktG), to the acquirer. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer. The agreement is subject to certain closing conditions, including the approval at the Company’s Extraordinary General Meeting. The sale of the assets to New Day Diagnostics is expected to enable the commercialization of Epi proColon “Next-Gen” and secure future cash flows for Epigenomics AG. As of September 14, 2023, Extraordinary General Meeting of Epigenomics approved the transaction. The closing of the agreement remains subject to customary closing conditions, and both parties are diligently working towards its completion. TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors. New Day Diagnostics, LLC completed the acquisition of Substantially all of Assets of Epigenomics AG on October 10, 2023.
お知らせ • Jul 26New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG.New Day Diagnostics, LLC entered into an asset purchase agreement to acquire Substantially all of Assets of Epigenomics AG on July 24, 2023. Under the terms of the agreement, New Day Diagnostics would acquire substantially all of Epigenomics AG’s assets and intellectual property. The acquisition would expand New Day Diagnostics' portfolio in the cancer diagnostics space and include proprietary biomarker technology for the detection of methylated DNA in various cancer indications, including Epi proColon, a screening tool for the non-invasive detection of colorectal cancer.TCB Capital Advisors, an affiliate of Weild & Co., acted as the exclusive financial advisor to New Day Diagnostics on this transaction, and Brock Shipe Klenk PLC, Orrick Herrington & Sutcliffe LLP, and Merchant & Gould acted as New Day Diagnostics' legal advisors.
お知らせ • Jun 13Epigenomics Shares Surge on Talks to Sell Nearly All Assets for $11.5mEpigenomics AG (XTRA:ECX1) shares more than doubled in value on June 12, 2023 after it said it is holding talks with an unidentified U.S. company to sell nearly all of its assets for around $11.5 million. The German medical diagnostic company said the potential deal, which is unbinding and therefore could still fail, relates to the patents and other rights of its blood tests to screen for colon cancer and all blood samples owned by Epigenomics. Current negotiations place the deal closing in December, Epigenomics said. The unidentified acquirer would also have to pay royalties and other costs associated with the potential commercialization of a diagnostic test in development.
お知らせ • May 20Epigenomics AG Announces Resignation of Andrew Lukowiak from the Company and the Executive Board Effective May 31, 2023Epigenomics AG announced that Member of the Executive Board, President, and Chief Scientific Officer Dr. Andrew Lukowiak, and the Company's Supervisory Board agreed on his resignation from the Company and the Executive Board effective May 31, 2023. Between now and the resignation date Dr. Lukowiak will continue to support the Company’s restructuring efforts in coordination with the Supervisory Board. The Company continues to be committed to maximizing the value of its technology through corporate partnering, licensing and/or asset sales. Dr. Lukowiak has been a Member of the Executive Board, President, and CSO of Epigenomics AG since December 2021. His broad contributions across the organization have been instrumental in furthering the Company’s colorectal cancer diagnostics’ program, including his systematic optimization of R&D structure and processes, as well as his execution of complementary partnerships. However, in recent months, in the current capital market environment, the Company has been unable to raise additional capital to secure funding for the FDA pivotal study of the "Next-Gen" test. In response, the restructuring of the Company was initiated on February 15, 2023 to minimize costs. Against this backdrop, the resignation of Dr. Andrew Lukowiak now also takes place.
お知らせ • Nov 09+ 2 more updatesEpigenomics AG to Report Q3, 2023 Results on Nov 09, 2023Epigenomics AG announced that they will report Q3, 2023 results on Nov 09, 2023